Biocon shares gained 2.05% to trade at ₹420.45, reflecting continued positive market response following the company's announcement of supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek single-dose prefilled autoinjectors. According to Moneycontrol, the stock is currently trading at ₹420.45, representing a notable uptick from its previous close and maintaining its position as a constituent of the Nifty Midcap 150 index. This regulatory milestone has generated sustained investor interest, with the approval expanding Biocon's US immunology portfolio for conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
Biocon's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjectors in two specific strengths: 45 mg/0.5 ml and 90 mg/ml. According to The Economic Times, this approval represents an expansion of the existing Yesintek product portfolio for the American market. The approval significantly enhances Biocon's portfolio of immunology products available in the U.S. market and underscores the company's dedication to improving global access to affordable medication options.
Yesintek was originally approved by the U.S. FDA on November 29, 2024, establishing its regulatory foundation in the American market. As reported by The Economic Times, the new single-dose prefilled autoinjector format offers patients another important treatment option and supports more tailored treatment approaches across different care settings and patient needs. A spokesperson for Biocon expressed the organisation's ongoing commitment to addressing the needs of patients worldwide, highlighting the positive impact of the FDA's recent approval in expanding treatment opportunities.
Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older. According to The Economic Times, the product is also approved for moderate to severely active Crohn's disease and ulcerative colitis in adults, addressing a range of debilitating autoimmune conditions that affect tens of thousands of Americans. These debilitating conditions affect tens of thousands of individuals across the United States, making Yesintek a vital treatment alternative for patients requiring effective solutions for various challenging health conditions.
Biocon shares have declined over 9% in 2026 so far, as reported by The Economic Times. However, in the longer term, Biocon shares have fallen over 4% over one year, but have delivered 19% returns over three years and 39% returns over five years. The company's recent quarterly results show consolidated revenue of ₹4,336 crore in Q1 FY27, representing a slight decrease from ₹4,516.60 crore in the preceding quarter. Net profit for the June 2026 quarter stood at ₹136.80 crore, an increase from ₹198.60 crore in March 2026 quarter. This supplemental approval enhances Biocon's comprehensive portfolio of immunology products in the United States and reaffirms the company's commitment to improving access to affordable medicines for patients around the world.
